David harel cytoreason
WebCytoreason employs 132 employees. The Cytoreason management team includes David Harel (Co-Founder and CEO), Yael Villa (Chief Technology Officer), and Rafael … WebCytoReason has 5 current employee profiles, including Co-Founder David Harel. David Harel Co-Founder. Shai Shen-Orr Chief Scientist. Yuval Kalugny VP Engineering. Renaud Gaujoux Co-founder & Lead Data Scientist. Elina Starosvetsky VP Biology.
David harel cytoreason
Did you know?
WebCurated profile of David Harel, Co-Founder and President, CytoReason including career history, news and intelligence, portfolio companies and investments. Thank you for …
WebSep 20, 2024 · Pharmaceutical giant Pfizer is making a $20 million investment in Israeli firm CytoReason, a developer of computational disease models for drug discovery and … Webinnovative drugs. CytoReason’s platform has provided Pfizer with multiple insights in a number of R&D programs across over 20 diseases. “It’s exciting to see our technology in the hands of such a stellar group of scientists,” said David Harel, CytoReason’s CEO and Co-founder. “Our work with the Pfizer team has
WebSep 20, 2024 · David Harel works as a Co-Founder & President at CytoReason, which is a Manufacturing company with an estimated 37 employees; and founded in 2016. They are part of the Executive team within the C-Suite Department and … WebJun 17, 2024 · CytoReason's computational model of the human body simulates human disease on a cellular level, minimizes the need for animal trials, and makes human trials …
WebMay 4, 2024 · CytoReason CEO David Harel discusses the limitations of animal studies, and the potential that alternative methods hold for the future of drug research and …
WebFounders: Shai Shen-Orr, David Harel, Renaud Gaujoux, Elina Starosvetsky, Yuval Kalugny, Ksenya Kveler Founded: 2016 Partnered: 2024 Website: www.cytoreason.com With one of the world's largest libraries of human molecular data, and a platform to make that data accessible and useful, CytoReason is able to turn data into actionable … liseth pensjonat \\u0026 hyttetunWebCytoReason develops a cell-centered computational model of the human body designed to discover complex patterns in biological data. The company collects proprietary data from … lisette claassenWebJan 23, 2024 · Sanofi will use CytoReason’s disease models to help identify assets for IBD, Crohn’s disease and ulcerative colitis. The resulting therapeutics could help the 70% of the patient population that has yet to find relief in current treatment options. The big challenge, Harel said, is to take chronic diseases and make them curable. bssa onlineWebAluf Yitzhak "Haki" Harel (Hebrew: יצחק הראל; born 1957) is the CEO of Israel Railways and former major general in the Israel Defense Forces.His last command post was the Planning Directorate.. Harel was born as … bssaiWebFeb 10, 2024 · CytoReason has established itself as a global leader in computational modeling of human diseases. The company's multidisciplinary team of 65 leading … bssa315k2sWebCytoReason has 7 executives. CytoReason's current Founder, Chief Executive Officer, President is David Harel. View All Management Team This profile has not been claimed. … lisette isayeWebFeb 10, 2024 · CytoReason's platform has provided Pfizer with multiple insights in a number of R&D programs across over 20 diseases. "It's exciting to see our technology in the hands of such a stellar group of scientists," said David Harel, CytoReason's CEO and Co-founder. "Our work with the Pfizer team has demonstrated how our computational … lisetta shah npi